



Chemoradiotherapy for Head and Neck Cancer

Guest Editor:

**Prof. Dr. Salvatore
Cappabianca**

Department of Precision
Medicine, University of Campania
"L. Vanvitelli", 80138 Naples, Italy

Deadline for manuscript
submissions:

closed (10 April 2022)

Message from the Guest Editor

Dear Colleagues,

Head and Neck cancer accounts for 4 percent of malignancies, with more than 650,000 cases and 330,000 death worldwide.

These diseases are usually managed by a multidisciplinary team, that includes medical oncologists, radiation oncologists, surgical oncologists, dedicated radiologists, and other specialists involved in the clinical management of these patients.

..

At the same time, recent developments in radiotherapy with the incorporation of intensity-modulated radiotherapy, molecular imaging-guided radiotherapy, adaptive radiotherapy, and proton therapy has the potential to decrease the long-term toxicity of this technique.

Finally, the immune system is known to have a pivotal role in this group of diseases, so that the PD-1 blockade represents a concrete option for the treatment of recurrent or metastatic head and neck cancers.

For this Special Issue, we welcome basic translational and clinical research papers, cancer biomarkers, professional opinions, and reviews in the broad field of locally advanced head and neck cancers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)